179 related articles for article (PubMed ID: 6376033)
1. The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes.
Kolterman OG; Olefsky JM
Diabetes Care; 1984; 7 Suppl 1():81-8. PubMed ID: 6376033
[TBL] [Abstract][Full Text] [Related]
2. Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus.
Beck-Nielsen H; Hjøllund E; Pedersen O; Richelsen B; Sørensen NS
Diabetes Care; 1984; 7 Suppl 1():100-5. PubMed ID: 6428842
[TBL] [Abstract][Full Text] [Related]
3. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.
DeFronzo RA; Simonson DC
Diabetes Care; 1984; 7 Suppl 1():72-80. PubMed ID: 6428844
[TBL] [Abstract][Full Text] [Related]
4. Sulfonylurea effects on target tissues for insulin.
McCaleb ML; Maloff BL; Nowak SM; Lockwood DH
Diabetes Care; 1984; 7 Suppl 1():42-6. PubMed ID: 6376028
[TBL] [Abstract][Full Text] [Related]
5. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
6. Insulin and IGF1 receptor function among type II diabetic responders and nonresponders to glyburide.
Grunberger G
J Lab Clin Med; 1993 Apr; 121(4):555-61. PubMed ID: 8454937
[TBL] [Abstract][Full Text] [Related]
7. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.
Rattarasarn C; Thamprasit A; Leelawattana R; Soonthornpun S; Setasuban W
J Med Assoc Thai; 2001 Dec; 84(12):1754-62. PubMed ID: 11999824
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous microdialysis before and after an oral glucose tolerance test: a method to determine insulin resistance in the subcutaneous adipose tissue in diabetes mellitus.
Rajamand N; Ungerstedt U; Brismar K
Diabetes Obes Metab; 2005 Sep; 7(5):525-35. PubMed ID: 16050945
[TBL] [Abstract][Full Text] [Related]
9. Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose.
Bavirti S; Tayek JA
Metabolism; 2003 Apr; 52(4):407-12. PubMed ID: 12701050
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic beta-cell function and insulin sensitivity in japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus.
Kanauchi M; Nakajima M; Saito Y; Kanauchi K
Metabolism; 2003 Apr; 52(4):476-81. PubMed ID: 12701062
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus.
Olefsky JM; Revers RR; Prince M; Henry RR; Garvey WT; Scarlett JA; Kolterman OG
Adv Exp Med Biol; 1985; 189():176-205. PubMed ID: 3898763
[TBL] [Abstract][Full Text] [Related]
13. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues.
Mandarino LJ; Gerich JE
Diabetes Care; 1984; 7 Suppl 1():89-99. PubMed ID: 6376034
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance in type II diabetes mellitus.
Rizza R; Butler P
Adv Second Messenger Phosphoprotein Res; 1990; 24():511-6. PubMed ID: 2169826
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
16. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
17. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights.
Vaag A
Dan Med Bull; 1999 Jun; 46(3):197-234. PubMed ID: 10421979
[TBL] [Abstract][Full Text] [Related]
18. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
20. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
